Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH120876, MH121959, MH128771)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Veterans Affairs (BX004758)
Article History
Received: 24 March 2023
Accepted: 29 February 2024
First Online: 4 April 2024
Competing interests
: AP received research funding support from Acadia Pharmaceuticals. Dr. Zarate is a full-time U.S government employee. He is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2 <i>R</i>,6 <i>R</i>)-hydroxynorketamine, (<i>S</i>)-dehydronorketamine, and other stereoisomeric dehydroxylated and hydroxylated metabolites of (<i>R,S</i>)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2 <i>R</i>,6 <i>R</i>)-hydroxynorketamine and (2 <i>S</i>,6 <i>S</i>)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorder. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. Dr. Quintanilla has no conflict of interest to disclose, financial or otherwise.